Lancet Respiratory Medicine

Article	Citations
Ensuring fair distribution of COVID-19 vaccines: is an intellectual waiver the answer?	701
How could we forget?	543
The Troublemaker	542
Long-term oxygen therapy in COPD: what is the evidence?	460
A new chance to treat rheumatoid arthritis lung fibrosis?	406
Postoperative CPAP after major abdominal surgery	397
European Society of Intensive Care Medicine (ESICM) LIVES 35th Annual Congress	358
Alone, lonely, and missed	358
Natalie Mazur—creating an affordable vaccine for RSV	346
Cystic fibrosis treatment: hope for all?	327
Standards for assessing and reporting adverse events	300
IL-6 blockade for COVID-19: a global scientific call to arms	291
Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis	284
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 s	269
Measles outbreak challenges Trump's public health vision	258
Paediatric pneumonia: catalysing research priorities for the next decade	254
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial	248
Risk and accuracy of outpatient-identified hypoxaemia for death among suspected child pneumonia cases in rural Bangladesh: a multifacility prospective cohort study	237
Social and environmental determinants of health inequities in childhood asthma	220
On the front lines of the sepsis crisis: hurdles faced by sepsis researchers, survivors, and family advocates	218
Home-based monitoring in chronic respiratory diseases: in search of Panacea	204
How Glasgow's 1957 tuberculosis screening programme could help countries today	196
Predicting benefit from adjuvant therapy with corticosteroids in community-acquired pneumonia: a data-driven analysis of randomised trials	195
What does the expanding CFTR modulator programme mean for people with cystic fibrosis?	194
Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial	188

Understanding clinical and biological heterogeneity to advance precision medicine in paediatric acute respiratory distress syndrome	186
Myopericarditis after COVID-19 vaccination: unexpected but not unprecedented	181
How to survive a pandemic	179
Concerns regarding a suggested long COVID paradigm – Authors' reply	179
Cystic fibrosis: a call for papers for ECFS 2022	177
A novel validated tool to score symptom burden in exercise-induced laryngeal obstruction: can we simplify patient follow-up and research?	172
Do chest x-ray-positive, sputum-negative individuals warrant more attention during tuberculosis screening?	171
The heart of the matter: modulating therapeutic effects of adrenomedullin in cardiogenic shock	166
First-line treatment for advanced NSCLC in older patients and those with poor performance status	162
Time to move away from an oxygen-centric model of pulmonary infarction?	161
2023 American Thoracic Society International Conference	156
Lifetime lung function trajectories and COPD: when the train derails	153
Addressing the origins and health effects of small lungs – Authors' reply	152
Saving our planet one puff at a time	149
Optimising eligibility criteria for lung cancer screening	149
The lung is not a balloon: the self-sealing property of the lung	147
US FDA delays decision on Juul and other leading e-cigarette brands	147
Baricitinib for patients with severe COVID-19—time to change the standard of care?	144
Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial	141
Tuberculosis prevalence: beyond the tip of the iceberg	140
Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK	140
Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis	135
Azithromycin for the prevention of chronic lung disease of prematurity: not a silver bullet	134
COVID-19 hospital admissions: Brazil's first and second waves compared	134
Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial	133
Pirfenidone in rheumatoid arthritis-associated interstitial lung disease – Authors' reply	130
Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers	129
Effect of an electronic nicotine delivery system with 0, 8, or 36 mg/mL liquid nicotine versus a cigarette substitute on tobacco-related toxicant exposure: a four-arm, parallel-group, randomised, cont	129
Major gaps in childhood pneumonia research priorities remain	128
RAS inhibition and COVID-19: more questions than answers?	127
How repeated influenza vaccination effects might apply to COVID-19 vaccines	125
Risk of COVID-19 hospital admission among children with asthma	125
Time to escalate quality assurance in small-cell lung cancer radiotherapy trials – Authors' reply	123
Once-per-day tacrolimus to reduce chronic lung transplant rejection	122
Opioids bring peace to patients with IPF cough	121
Early exposure to general anaesthesia: considerations for age-related vulnerability and behavioural outcomes	120
The course of action for effective anti-cytokine treatment in COVID-19	120
Trends in COVID-19-related in-hospital mortality: lessons learned from nationwide samples	118
Could a good night's sleep improve COVID-19 vaccine efficacy?	117
A leap forward in assessing host-directed therapies for tuberculosis	117
Moving from collective to distributed epidemiological cancer research	115
European Respiratory Society International Congress 2021	114
Easing the stress of chronic cough	114
Respiratory support before venovenous ECMO for COVID-19: what is the price?	113
The burden of tuberculosis in Libya	112
Inhaled corticosteroids: not just for asthma, but for COVID-19?	112
The elusive goal of COVID-19 vaccine immunity	111
European Respiratory Society International Congress 2022	111
Rapid maxillary expansion in paediatric obstructive sleep apnoea	111
Emily Stone—from lung cancer screening to tobacco control	107

US FDA plans improved tobacco regulation	106
Hans: finding acceptance and positivity in mindfulness	104
Advancement of asthma management in the past decade	104
US Senate committee investigates asthma inhaler prices	103
FLiRTing with danger as SARS-CoV-2 variants evolve	103
Lung transplantation for COVID-19-associated ARDS	102
Multiplex bacterial PCR for antibiotic stewardship in pneumonia	101
Chronic obstructive pulmonary disease: 10 years of precision-guided success	101
COVID-19, smoking, and cancer: a dangerous liaison	100
Pulmonary manifestations of chronic HPV infection in patients with recurrent respiratory papillomatosis	99
US EPA strengthens PM2·5 air pollution limits	99
Changing how we see COPD	98
Knowledge gaps in fibrotic interstitial lung disease in pan-Asian populations: data not missing at random?	96
The persistent mismeasure of spirometry in women	96
Treatment of severe COVID-19: a role for JAK and complement inhibitors?	96
Discussions on VT4COVID	96
Interstitial lung disease: a decade of progress and hope	95
Deji Adegunsoye—tackling the mysteries of pulmonary fibrosis	95
Fatal dyspnoea at the Palace of Versailles	94
Anti-CTLA-4 in non-small-cell lung cancer: insights from the NIPPON study	93
Video laryngoscopy is not the nemesis of direct laryngoscopy	93
Serotonin pathway blockade in pulmonary arterial hypertension	93
Broad protection from SARS-CoV-2 variants without antigen matching	92
Air pollution, climate change, and lung health in Europe	92
Convalescent plasma in outpatients with COVID-19	91
Lockdown as the mother of invention: disruptive technology in a disrupted time	90
European Respiratory Society International Congress 2023	89
Integrating morphology and treatable traits into the management of ILD	88
Discussions on VT4COVID	88
Blood eosinophil-guided therapy for COPD exacerbations	87
Optimising the approach to ILD diagnosis: the balance of procedural complications against diagnostic accuracy	86
Undetected COVID-19 cases in Africa	84
Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multi	84
Vascular mechanisms and manifestations of COVID-19	84
Historic TB outbreak a wake-up call for US policy makers	83
COVID-19 boosters versus primary series: update to a living review	83
Chronic cough and cough hypersensitivity: from mechanistic insights to novel antitussives	83
Online mindfulness-based cognitive therapy for fatigue in patients with sarcoidosis (TIRED): a randomised controlled trial	82
Remdesivir saves lives. Were 3 years needed to learn that?	82
Interpreting posterior probabilities in Bayesian analyses of clinical trials	82
Respiratory diseases advocate living with severe asthma	82
Thoracentesis: an old story and some new sources	81
Empirical antibiotic therapy for sepsis: save the anaerobic microbiota	81
Lifetime non-smoker survives stage IV lung cancer four times	81
The global burden of pulmonary arterial hypertension: profound but improving?	80
New framework to define the spectrum of tuberculosis	79
Top ten research priorities for breathlessness research: UK James Lind Alliance priority setting partnership	79
MARS 2 trial: the future of pleurectomy decortication in pleural mesothelioma	79
High-dose rifampicin to treat tuberculosis infection: potential and pitfalls	79
Leveraging the pleural space for anticancer therapies in pleural mesothelioma	79
Concerns about PRISm	78
Fighting for air: racial inequity in respiratory health	77
Moving the pathway goalposts: COPD as an immune-mediated inflammatory disease	77
Artificial intelligence hold promise in the ICU	75
Respiratory syncytial virus-induced disease in healthy infants: we need to offload this burden	75
VV-ECMO in severe COVID-19: multidimensional perspectives on the use of a complex treatment	72
The past 10 years of cystic fibrosis treatment: the road to cure	72
Restricted spirometry through the lifespan	71
Face masks: all for one and one for all	71
Potential for personalised and biomarker-guided COPD self-treatment approaches	70
Use of point-of-care testing for respiratory viruses in hospital	69
Pause for thought: navigating the complex scientific domains of fatigue and of mindfulness-based practices in sarcoidosis and beyond	69
Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study	69
The role of antiviral treatment in the COVID-19 pandemic	68
It is time to include real-world effectiveness data on medicinal product labels	68
Why has the incidence of tuberculosis not reduced in London during the COVID-19 pandemic?	68
Daily use of lateral flow devices by contacts of confirmed COVID-19 cases to enable exemption from isolation compared with standard self-isolation to reduce onward transmission of SARS-CoV-2 in Englan	67
Transitioning to gaseous and liquid fuels: a right step towards clean cooking in low-income and middle-income countries	65
Concerns regarding a suggested long COVID paradigm	65
Correction to Lancet Respir Med 2024; 12: 129–40	63
Correction Lancet Respir Med 2022; 10: 937–48	62
Correction to Lancet Respir Med 2020; 8: 696–708	62
Correction to Lancet Respir Med 2019; 7: 745–56	61
Correction to Lancet Respir Med 2021; published online Feb 10. https://doiorg/10.1016/S2213-2600(20)30510-5	60
Correction to Lancet Respir Med 2022; 10: 761–75	60
Correction to Lancet Respir Med 2021; published online Sept 1. https://doi.org/10.1016/S2213-2600(21)00331-3	59
Correction to Lancet Respir Med 2024; 12: 642–54	58
Treating COVID-19-related breathlessness with novel interventions	58
Rituximab for connective tissue disease-associated interstitial lung disease	58
Correction to Lancet Respir Med 2024; 12: 183–85	58

Correction to Lancet Respir Med 2023; 11: 163–75	58
Correction to Lancet Respir Med 2022; 10: 679–88	57
Savolitinib in NSCLC: progress in the MET exon 14 journey	56
Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial	56
Correction to Lancet Respir Med 2024; 12: 799–809	56
Correction to Lancet Respir Med 2022; 10: 650–60	56
Correction to Lancet Respir Med 2022; 10: e36–37	56
An overview of influenza H5 vaccines	55
Should we ration extracorporeal membrane oxygenation during the COVID-19 pandemic?	54
Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis	54
3-year outcomes of discharged survivors of COVID-19 following the SARS-CoV-2 omicron (B.1.1.529) wave in 2022 in China: a longitudinal cohort study	54
Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial	53
Tuberculosis and nutrition: what gets measured gets managed	52
Concerns regarding a suggested long COVID paradigm	52
Withdrawal of life sustaining therapies in patients with or without acute brain injury	52
The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial	51
Australia bans engineered stone to prevent silicosis	51
Licensure laws and other barriers to telemedicine and telehealth: an urgent need for reform	50
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial	50
Extracorporeal cardiopulmonary resuscitation versus conventional cardiopulmonary resuscitation in adults with cardiac arrest: a comparative meta-analysis and trial sequential analysis	50
Long COVID: systemic inflammation and obesity as therapeutic targets	49
Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials	48
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial	47
Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-	47
Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled	46
Longitudinal lung function and gas transfer in individuals with idiopathic pulmonary fibrosis: a genome-wide association study	46
Risk factors for COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis	46
A2BCD: a concise guide for asthma management	45
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomise	45
WHO ends the COVID-19 public health emergency	45
Interleukin-6: obstacles to targeting a complex cytokine in critical illness	45
SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): a series of cross-sectional random community surveys	45
To boost or not to boost: navigating post-pandemic COVID-19 vaccination	45
Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial	44
Outcome predictors and patient progress following delivery in pregnant and postpartum patients with severe COVID-19 pneumonitis in intensive care units in Israel (OB-COVICU): a nationwide cohort study	44
In-hospital and 6-month outcomes in patients with COVID-19 supported with extracorporeal membrane oxygenation (EuroECMO-COVID): a multicentre, prospective observational study	43
Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study	43
One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort study	43
Use of fibrinolytics and deoxyribonuclease in adult patients with pleural empyema: a consensus statement	43
Eat or heat: fuel poverty and childhood respiratory health	43
GOLD report: 2022 update	42
Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials	42
Geography, generalisability, and susceptibility in clinical trials	42
Towards shorter, safer, flexible, and more effective treatment regimens for drug-resistant tuberculosis	42
Respiratory sequelae of COVID-19: pulmonary and extrapulmonary origins, and approaches to clinical care and rehabilitation	41
First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phas	40
Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study	40
Adaptive servo-ventilation for sleep-disordered breathing in patients with heart failure with reduced ejection fraction (ADVENT-HF): a multicentre, multinational, parallel-group, open-label, phase 3 r	39
“Yes! We can end TB,” but remember the sequelae in children	39
Addressing the post-acute sequelae of SARS-CoV-2 infection: a multidisciplinary model of care	39
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study	39
Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment	38
Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials	38
Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations	38
Fast multiplex bacterial PCR of bronchoalveolar lavage for antibiotic stewardship in hospitalised patients with pneumonia at risk of Gram-negative bacterial infection (Flagship II): a multicentre, ran	38
Advancing precision medicine for acute respiratory distress syndrome	38
Improving COVID-19 vaccine immunogenicity by interrupting methotrexate treatment	37
The 2021 USPSTF lung cancer screening guidelines: a new frontier	37
Befotertinib—a viable alternative in EGFR-mutant advanced NSCLC?	37
Misdiagnosis of sarcoidosis	37
Vaccination in the world's top athletes	36
US CDC plans to relax COVID-19 isolation guidelines	35
Tuberculosis, conflict, and displacement	35
Trouble with promoting lung cancer screening in never-smokers – Authors' reply	35
Health effects of gas fuels: interpreting evidence from a comprehensive meta-analysis	35
Genetic associations and lung function in IPF: unexpected answers, persistent questions	34
Health promotion in the management of respiratory diseases: an Indian perspective	34
Monoclonals for patients hospitalised with COVID-19	34
Tracing and vaccinating: how to REACT to COVID-19 pandemic	34
Mixed news on air pollution and child lung health	34
The role of growth and nutrition in the early origins of spirometric restriction in adult life: a longitudinal, multicohort, population-based study	33
Phenotypes of idiopathic pulmonary arterial hypertension	33
Early postnatal high-dose fat-soluble enteral vitamin A supplementation for moderate or severe bronchopulmonary dysplasia or death in extremely low birthweight infants (NeoVitaA): a multicentre, rando	33
Viable virus shedding during SARS-CoV-2 reinfection	33
Re-evaluating the role of CPAP in OSA management amid obesity pharmacology advancements	33
Is tezepelumab the ubiquitous biologic for severe asthma?	33
Adrenal insufficiency in patients taking benralizumab as corticosteroid sparing therapy – Authors' reply	33
Is low-risk status a surrogate outcome in pulmonary arterial hypertension? An analysis of three randomised trials	33
Endoscopic sinus surgery with medical therapy versus medical therapy for chronic rhinosinusitis with nasal polyps: a multicentre, randomised, controlled trial	32
Community-acquired pneumonia: the best candidates for clarithromycin – Authors' reply	32
The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease	32
Confounding undermines inferences of preventive therapy effectiveness among subgroups of tuberculosis contacts	32
Long-term safety of lumacaftor–ivacaftor in children aged 2–5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study	32
Smoking, nicotine, and COVID-19	32
Association of novel adult cough subclasses with clinical characteristics and lung function across six decades of life in a prospective, community-based cohort in Australia: an analysis of the Tasmani	31
Lung transplantation for COVID-19-associated ARDS – Authors' reply	31
Transbronchial cryobiopsy followed by as-needed surgical lung biopsy versus immediate surgical lung biopsy for diagnosing interstitial lung disease (the COLD study): a randomised controlled trial	31
Integrating new therapies for systemic sclerosis-associated lung fibrosis in clinical practice	31
The 2023 UN high-level meeting on tuberculosis: renewing hope, momentum, and commitment to end tuberculosis	31
Severe COVID-19 pneumonitis and timing of birth in women	31
Authors' reply	30
Prone positioning might reduce the need for intubation in people with severe COVID-19 – Authors' reply	30
Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial	30
New guidelines for paediatric intensive care unit patients	30
Alex Mazulov—battling bronchiectasis in wartime Ukraine	29